Management ChangeJun 23, 2026, 09:12 AM
Illumina Appoints Daniel M. Skovronsky to Board of Directors
AI Summary
Illumina, Inc. announced the appointment of Daniel M. Skovronsky, M.D., Ph.D., to its Board of Directors, effective June 16, 2026. The Board's size was increased from nine to ten members to accommodate the new appointment. Dr. Skovronsky, who is the Chief Scientific and Product Officer of Eli Lilly and Company, brings extensive experience in drug discovery and clinical development to Illumina's board. He qualifies as an independent director and will participate in the non-employee director compensation programs.
Key Highlights
- Illumina's Board of Directors increased from nine to ten members.
- Daniel M. Skovronsky, M.D., Ph.D., was appointed to the Board.
- The appointment was effective immediately on June 16, 2026.
- Dr. Skovronsky serves as Chief Scientific and Product Officer at Eli Lilly and Company.
- He qualifies as an independent director under Nasdaq and SEC rules.
- He will stand for election at the Company's 2027 annual meeting of stockholders.
Price Impact
More from ILMN